Renal Cell Carcinoma

Molecular Targets and Clinical Applications

  • Ronald M. Bukowski
  • Robert A. Figlin
  • Robert J. Motzer

Table of contents

  1. Front Matter
    Pages i-xvii
  2. Ronald M. Bukowski, Robert A. Figlin, Robert J. Motzer
    Pages 1-12
  3. Nadeem Dhanani, Cathy Vocke, Gennady Bratslavsky, W. Marston Linehan
    Pages 13-33
  4. Thomas E. Hutson, Snehal Thakkar, Peter Cohen, Ernest C. Borden
    Pages 49-78
  5. W. Kimryn Rathmell, Brian I. Rini
    Pages 99-118
  6. John S. Lam, Robert A. Figlin, Arie S. Belldegrun
    Pages 119-149
  7. Robert J. Motzer
    Pages 151-165
  8. Saby George, Ronald M. Bukowski
    Pages 167-187
  9. Vanitha Ramakrishnan, Vinay Bhaskar, Melvin Fox, Keith Wilson, John C. Cheville, Barbara A. Finck
    Pages 195-209
  10. Brian Shuch, Arie S. Belldegrun, Robert A. Figlin
    Pages 211-229
  11. J. C. Oosterwijk-Wakka, Otto C. Boerman, Peter F. A. Mulders, Egbert Oosterwijk
    Pages 231-247
  12. Karen L. Reckamp, Robert A. Figlin, Robert M. Strieter
    Pages 249-265
  13. Daniel Cho, James W. Mier, Micheal B. Atkins
    Pages 267-285
  14. Eric Jonasch, Cheryl Lyn Walker
    Pages 287-303
  15. Jorge A. Garcia, Susan A. J. Vaziri, Ram Ganapathi
    Pages 305-320
  16. Benedetta Peruzzi, Jean-Baptiste Lattouf, Donald P. Bottaro
    Pages 321-334
  17. Yoichi Mizutani, Akihiro Kawauchi, Benjamin Bonavida, Tsuneharu Miki
    Pages 335-346

About this book

Introduction

In the second edition of their critically acclaimed book, Ronald Bukowski, Robert Motzer, and Robert Figlin have thoroughly updated and expanded their survey of clinical, biological and pathological management of localized and advanced renal cell carcinoma. A panel of internationally renowned contributors explores the latest developments in molecular genetics, focusing on the novel targets that have been discovered in epithelial renal tumors. The discussion includes the specific biology of selected target molecules or receptors and the various agents that inhibit these targets, including full chapters devoted to drugs that selectively inhibit receptor tyrosine kinases, such as sunitinib and axitinib. Further attention is paid to leading-edge strategies that target and inhibit tumor associated angiogenesis and block the vascular endothelial growth factor pathway. Comprehensive and authoritative, Renal Cell Carcinoma: Molecular Targets and Clinical Applications, Second Edition is the definitive text on the rapidly evolving landscape of experimental therapeutics, written and edited by the pioneers of the field.

Keywords

Angiogenesis Inhibition Carcinom Epithelial Renal Tumors Molecular Medicine Novel Targets Renal Cell Carcinoma Staging Tyrosine Kinase Inhibition VEGF Pathway

Editors and affiliations

  • Ronald M. Bukowski
    • 1
  • Robert A. Figlin
    • 2
  • Robert J. Motzer
    • 3
  1. 1.Cleveland Clinic FoundationCleveland Clinic Taussig Cancer Center and CCF Lerner College of Medicine of CWRUCleveland
  2. 2.Division of Medical Oncology & Experimental TherapeuticsCity of Hope National Medical, Center/Beckman Research InstituteDuarte
  3. 3.Memorial-Sloan Kettering Cancer CenterNew York

Bibliographic information

  • DOI https://doi.org/10.1007/978-1-59745-332-5
  • Copyright Information Humana Press 2009
  • Publisher Name Humana Press
  • eBook Packages Medicine
  • Print ISBN 978-1-58829-737-2
  • Online ISBN 978-1-59745-332-5
  • About this book